The first-ever CRISPR-based gene-editing therapy has been approved for marketing ... before reinfusing them to treat the diseases. The aim of the treatment is to modify the cells to make foetal ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

A cutting-edge gene therapy has been approved for NHS use for some patients with severe sickle cell disease. Casgevy, also ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...

Exagamglogene autotemcel (exa-cel) gene therapy offers a potential cure for severe sickle cell disease, now available on NHS.

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the ...

Casgevy, also known as exa-cel, was the first treatment to be licensed using gene-editing tool Crispr ... has been approved for use for certain patients with severe sickle cell disease.

Britain's MHRA medical regulator in 2023 became the first in the world to approve ... tool CRISPR. NICE, which assesses whether new medical technologies can be used in the NHS, said the treatment ...